GT
ORKA

Glenmede Trust’s Oruka Therapeutics ORKA Stock Holding History

Glenmede Trust’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Buy
21,772
+2,287
+12% +$79.5K 0.01% 719
2025
Q4 		$591K Buy
+19,485
New +$543K ﹤0.01% 890

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Glenmede Trust's ORKA Position: Q1 2026 in Review

Glenmede Trust increased its Oruka Therapeutics (ORKA) stake by 12% in Q1 2026, buying an estimated $79.5K and bringing the position to 21,772 shares worth $1.07M. The position accounts for 0.01% of the portfolio, ranked #719.

Glenmede Trust first reported a position in ORKA in Q4 2025 and has held it in 2 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Glenmede Trust held 21,772 shares of Oruka Therapeutics worth $1.07M as of Q1 2026.
  • Glenmede Trust bought 2,287 Oruka Therapeutics shares in Q1 2026, an estimated $79.5K.
  • Oruka Therapeutics made up 0.01% of Glenmede Trust's portfolio in Q1 2026, its #719 holding.
  • Glenmede Trust first reported a position in Oruka Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.